M. Mokyr

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Margalit Birnbaum Mokyr, Margalitb. Mokyr, M B Mokyr, M. B. Mokyr, Margalit B Mokyr, Margalit B. Mokyr
Publication record
117 papers · 2,195 citations · H-index 28

PAPERS

to in Vitro Activation Bearer Spleen Cells by Depletion of Glass-adherent Cells Prior Augmentation of Antitumor Cytotoxicity in MOPC-315 Tumor
20130 citationsauthor #1
Abstract 4755: Importance of an induction dose to the immunogenicity of cancer vaccines: A reverse translational study
20100 citationsauthor #3
The Xeroderma Pigmentosum Group E Gene Product DDB2 Activates Nucleotide Excision Repair by Regulating the Level of p21Waf1/Cip1
200761 citationsauthor #4
Talactoferrin alfa is an anti-cancer agent with activity in renal cell cancer (RCC) patients and a novel immunomodulatory mechanism of action.
20063 citationsauthor #8
; Realizationof theTherapeuticPotentialof CTLA-4Blockadein Low-Dose Chemotherapy-treated Tumor-bearing Mice1
20060 citationsauthor #1
Augmentation of Antitumor Cytotoxicity in MOPC-315 Tumor Bearer Spleen Cells by Depletion of Glass-adherent Cells Prior to in Vitro I
20060 citationsauthor #1
Importance of signaling via the IFN-α/β receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor
200612 citationsauthor #1
Talactoferrin Alfa, a novel immunomodulatory agent with anti-cancer activity in phase II clinical trials.
20060 citationsauthor #6
Cyclophosphamide-inducedAppearanceof ImmunopotentiatingT-Cells in the Spleens of Mice Bearinga Large MOPC-315Tumor1
20060 citationsauthor #2
Effect of Polyethylene Glycol 6000 on the Generation of Antitumor Cytotoxicity in MOPC-315 Tumor Bearer Spleen Cells Cultured in the Presence or Absence of Inactivated Stimulator Tumor Cells1
20060 citationsauthor #2
Role of AntitumorImmunityin Cyclophosphamide-inducedRejectionof Subcutaneous Nonpalpable MOPC-315 Tumors1
20060 citationsauthor #1
Effect of Polyethylene Glycol 6000 on the Generation of Antitumor Cytotoxicity in MOPC-315 Tumor Bearer Spleen Cells Cultured in the Presence or Absence of Inactivated Stimulator Tumor Cells 1
20060 citationsauthor #2
Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy
20052 citationsauthor #3
Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers
20054 citationsauthor #4
Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy
20052 citationsauthor #5
Enhanced expansion of the thymic CD8+ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers
20053 citationsauthor #3
Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor
20053 citationsauthor #3
Characterization of the exogenous interleukin-2 requirements for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers
20053 citationsauthor #2
Suppression of antitumor immunity by macrophages in spleens of mice bearing a large MOPC-315 tumor
200412 citationsauthor #2
Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor
200413 citationsauthor #4
Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor
20042 citationsauthor #4
Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan
20044 citationsauthor #2
Importance of IL-10 for CTLA-4-Mediated Inhibition of Tumor-Eradicating Immunity1
200453 citationsauthor #4
Inhibition of Tumor-Eradicating Immunity Importance of IL-10 for CTLA-4-Mediated and
20040 citationsauthor #1
Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers
20049 citationsauthor #1
Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth
200429 citationsauthor #3
Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas
20047 citationsauthor #2
Melphalan-induced up-regulation of B7–1 surface expression on normal splenic B cells
200317 citationsauthor #4
Anti-metastatic activity of hapten-modified autologous tumor cell vaccine in an animal tumor model
200214 citationsauthor #3
Melphalan-Induced Expression of IFN-β in MOPC-315 Tumor-Bearing Mice and Its Importance for the Up-Regulation of TNF-α Expression1
200116 citationsauthor #2
Mechanism of Melphalan-Induced B7-1 Gene Expression in P815 Tumor Cells1
200136 citationsauthor #4
Melphalan-induced expression of IFN-beta in MOPC-315 tumor-bearing mice and its importance for the up-regulation of TNF-alpha expression.
20017 citationsauthor #2
Expression in P 815 Tumor Cells Mechanism of Melphalan-Induced B 7-1 Gene Bluestone and
20011 citationsauthor #4
B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells
20005 citationsauthor #3
TumorUp-Regulate B 7-1 Gene Expression in Melphalan and Other Anticancer Modalities and
20000 citationsauthor #4
Melphalan and Other Anticancer Modalities Up-Regulate B7-1 Gene Expression in Tumor Cells1
200064 citationsauthor #4
Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
199934 citationsauthor #4
Norepinephrine-mediated inhibition of antitumor cytotoxic T lymphocyte generation involves a beta-adrenergic receptor mechanism and decreased TNF-alpha gene expression.
199948 citationsauthor #2
T Cell-Dependent Mechanism + CD 8 B 7-1-Transfected P 815 Tumor Cells Via a Contribute to the Eradication of Host B 7-1 and B 7-2 Costimulatory Molecules and
19994 citationsauthor #4
Signaling through CD40 enhances cytotoxic T lymphocyte generation by CD8+ T cells from mice bearing large tumors
19999 citationsauthor #3
Norepinephrine-Mediated Inhibition of Antitumor Cytotoxic T Lymphocyte Generation Involves a β-Adrenergic Receptor Mechanism and Decreased TNF-α Gene Expression
199977 citationsauthor #2
Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
199816 citationsauthor #4
Large MOPC-315 Tumor Tumor-Eradicating Immunity by Mice Bearing a Melphalan-Induced Acquisition of Importance of the B 7-2 Molecule for Low Dose
19980 citationsauthor #1
Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.
199827 citationsauthor #1
Limited importance of CD40/CD40L interaction in the B7-dependent generation of anti-MOPC-315 cytotoxic T lymphocyte activity by tumor bearer splenic cells stimulated in vitro in the presence of tumor necrosis factor
19986 citationsauthor #2
Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.
1998152 citationsauthor #1
Potentiation of antitumor CTL response by GM-CSF involves a B7-dependent mechanism.
199713 citationsauthor #1
Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule
199634 citationsauthor #6
Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells.
199658 citationsauthor #3
Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon γ in the therapeutic outcome
199513 citationsauthor #2
Neurotransmitter suppression of the in vitro generation of a cytotoxic T lymphocyte response against the syngeneic MOPC-315 plasmacytoma
199521 citationsauthor #2
Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.
199529 citationsauthor #4
Insight into the mechanism of TCR-V beta 8+/CD8+ T cell-mediated MOPC-315 tumor eradication.
199412 citationsauthor #1
Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor
199435 citationsauthor #3
Cooperation between staphylococcal enterotoxin B and low dose melphalan in the cure of mice bearing a large MOPC-315 tumor and extensive metastases.
19942 citationsauthor #5
Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.
199422 citationsauthor #3
Transforming growth factor-β-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy
19941 citationsauthor #3
Two tumor models of curative adoptive chemoimmunotherapy using tumor-infiltrated spleen cells with potent antitumor cytotoxicity stimulated by antigen-sharing tumors
19930 citationsauthor #3
Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
199322 citationsauthor #1
Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan‐treated BALB/C mice bearing a large MOPC‐315 tumor
19924 citationsauthor #2
Neurotransmitter Suppression of the In Vitro Generation of the Cytotoxic T-Lymphocyte Response Against Syngeneic MOPC-315 Plasmacytomas by Spleen Cells from Melphalan-Cured MOPC-315 Tumor Bearers (Catecholamine Inhibition of Tumor Immunity Following Chemotherapy)
19910 citationsauthor #2
Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured, antigen-activated, tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas.
19915 citationsauthor #3
Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.
199045 citationsauthor #3
Phorbol ester mediated enhancement in the lytic activity exerted by lyt 2 positive splenic t cells as a consequence of melphalan therapy of mopc 315 tumor bearing mice
19890 citationsauthor #4
Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers.
19893 citationsauthor #1
Enhancement of the effectiveness of Lyt-2+ T-cells for adoptive chemoimmunotherapy by short-term exposure of tumor-bearer spleen cells to polyethylene glycol and/or melphalan.
19894 citationsauthor #2
Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
19890 citationsauthor #4
Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.
198943 citationsauthor #1
Cyclophosphamide and melphalan as immunopotentiating agents in cancer therapy
198917 citationsauthor #2
Can the bad guys be defeated?
19880 citationsauthor #1
Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
198819 citationsauthor #2
Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes co-expressing the Lyt 2 and the L3T4 antigens.
198715 citationsauthor #3
Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
19876 citationsauthor #3
Interplay between the toxic effects of anticancer drugs and host antitumor immunity in cancer therapy.
198733 citationsauthor #1
The MOPC-315 tumor as a model for the immunomodulatory effects of cyclophosphamide.
19874 citationsauthor #1
Ability of cyclophosphamide in the absence of cross-linking activity to exert the immunomodulatory effect required for the cure of mice bearing a large MOPC-315 tumor.
198614 citationsauthor #1
Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.
198516 citationsauthor #1
IMMUNOMODULATION BY A LOW DOSE OF CYCLOPHOSPHAMIDE AS THE PRIMARY MECHANISM FOR THE CURE OF MICE BEARING A LARGE METASTATIC MOPC-315 TUMOR1
19850 citationsauthor #1
Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
198510 citationsauthor #1
Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
198423 citationsauthor #2
Immunomodulation by Cyclophosphamide and its Effect on Eradication of Established Tumors
19844 citationsauthor #2
Cyclophosphamide-mediated selective elimination of suppressor cell activity from the spleen of mice bearing a large mopc-315 tumor. Abstr.
19831 citationsauthor #1
Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
198367 citationsauthor #1
Mode of action of polyethylene glycol 6000 in potentiating the in vitro generation of antitumor cytotoxicity by MOPC-315 tumor bearer spleen cells.
19823 citationsauthor #1
Melphalan is more effective in curing mice which bear late large rather than early small MOPC-315 plasmacytomas
19820 citationsauthor #2
Studies of the mechanism by which polyethylene glycol 6000 (peg) promotes the generation of antitumor immunity in mopc-315 tumor bearer spleen cells. Abstr.
19820 citationsauthor #1
Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
198267 citationsauthor #1
The role of host anti-tumor immunity in cyclophosphamide induced rejection of nonpalpable mopc-315 tumors. Abstr.
19810 citationsauthor #1
Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.
1981114 citationsauthor #2
Cooperation between cyclophosphamide cytotoxic effects and host anti-tumor immunity in the cure of mice bearing large size sc mopc-315 tumors. Abstr.
19818 citationsauthor #3
Effect of polyethylene glycol 6000 on the generation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells cultured in the presence or absence of inactivated stimulator tumor cells.
19807 citationsauthor #2
Importance of timing of cyclophosphamide (cy) therapy for curing mopc-315 tumor-bearing mice. Abstr.
19807 citationsauthor #2
Opposite effects of different strains or batches of same strain of BCG on in vitro generation of syngeneic and allogeneic antitumor cytotoxicity.
198013 citationsauthor #1
Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
198089 citationsauthor #2
Specific and non‐specific immunologic mechanisms of tumor growth facilitation
198015 citationsauthor #3
Augmenting antitumor cytotoxicity of tumor-bearer spleen cells by polyethylene glycol 6000 (peg).
19800 citationsauthor #2
Augmentation of antitumor cytotoxicity of MOPC-315 tumor bearer spleen cells by depletion of dinitrophenol-adherent cells prior to in vitro immunization.
197930 citationsauthor #1
Augmenting anti-tumor cytotoxicity of tumor-bearer spleen cells. Abstr.
19792 citationsauthor #1
Augmentation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells by depletion of glass-adherent cells prior to in vitro activation.
197932 citationsauthor #1
Antitumor immunity in strain 2 guinea pigs immunized with potassium chloride extracts of L2C tumor cells.
19784 citationsauthor #3

TIMELINE

1972 24 citations

1973 117 citations

1974 157 citations

1975 75 citations

1977 36 citations

1978 47 citations

1979 64 citations

1980 131 citations

1981 122 citations

1982 70 citations

1983 68 citations

1984 27 citations

1985 26 citations

1986 14 citations

1987 58 citations

1988 19 citations

1989 67 citations

1990 45 citations

1991 5 citations

1992 4 citations

1993 22 citations

1994 72 citations

1995 63 citations

1996 92 citations

1997 13 citations

1998 201 citations

1999 172 citations

2000 69 citations

2001 60 citations

2002 14 citations

2003 17 citations

2004 129 citations

2005 17 citations

2006 15 citations

2007 61 citations

2010 0 citations

2013 0 citations

M. Mokyr

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT